ticagrelor (Q420542)

Ticagrelor (English)

19 November 2016

CCCSC1=NC2=C(C(=N1)NC3CC3C4=CC(=C(C=C4)F)F)N=NN2C5CC(C(C5O)O)OCCO

1 reference

Ticagrelor (English)

19 November 2016

CCCSC1=NC2=C(C(=N1)N[C@@H]3C[C@H]3C4=CC(=C(C=C4)F)F)N=NN2[C@@H]5C[C@@H]([C@H]([C@H]5O)O)OCCO

1 reference

Ticagrelor (English)

19 November 2016

0.18 gram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=B01AC24

active ingredient in

Brilique

1 reference

European Medicines Agency product number

EMEA/H/C/001241

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001241/human_med_001398.jsp

European Medicines Agency product number

22 March 2017

Possia

1 reference

EMEA/H/C/002303

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002303/human_med_001399.jsp

22 March 2017

1 reference

14 February 2018

World Health Organisation international non-proprietary name

ticagrelor (English)

1 reference

ticagrelor (English)

medical condition treated

19 October 2016

acute myocardial infarction

1 reference

2 October 2018

unstable angina

1 reference

2 October 2018

acute coronary syndrome

1 reference

2 October 2018

heart disease

1 reference

significant drug interaction

2 October 2018

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vortioxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibrutinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

paroxetine

1 reference

probably

A reference set of clinically relevant adverse drug-drug interactions

sertraline

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluvoxamine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluoxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

probably

A reference set of clinically relevant adverse drug-drug interactions

aspirin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

anagrelide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

enoxaparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dalteparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

urokinase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tinzaparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rac-warfarin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fondaparinux

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alteplase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

heparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acenocoumarol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenindione

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenecteplase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Streptokinase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rivaroxaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apixaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Purinergic receptor P2Y12

subject has role

antagonist

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

1765

17 August 2016

legal status (medicine)

boxed warning

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

imported from Wikimedia project

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

US pregnancy category C

1 reference

English Wikipedia

mass

522.186 dalton

1 reference

xenobiotic-transporting ATPase inhibitor

Ticagrelor (English)

19 October 2016

1 reference

5 March 2018

purinergic P2Y receptor antagonists

1 reference

InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

Medical Subject Headings

15 March 2018

Ticagrelor

0 references

Identifiers

InChI

1 reference

Ticagrelor (English)

19 November 2016

2 references

Ticagrelor (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

274693-27-5

2 references

Global Substance Registration System

UNII

GLH0314RVC

ticagrelor (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=274693-27-5

10 April 2021

1 reference

Ticagrelor (English)

19 November 2016

2 references

Ticagrelor (English)

19 November 2016

InChIKey

Reaxys registry number

15468079

1 reference

ticagrelor (English)

19 October 2016

mapping relation type

2 references

TICAGRELOR (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

1 reference

TICAGRELOR (English)

19 November 2016

2 references

inferred from InChIKey

InChIKey

Hazardous Substances Data Bank

1 reference

1 reference

28 October 2019

Ticagrelor (English)

10 May 2021

1 reference

InChIKey

DSSTOX compound identifier

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.114.746

27 December 2018

ECHA Substance Infocard ID

(1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (English)

quotation

CAS no.: 274693-27-5 (English)

100.114.746

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.114.746

27 December 2018

(1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (English)

quotation

CAS no.: 274693-27-5 (English)

1 reference